DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 91 filers reported holding DYNE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,140,086 | -20.4% | 1,912,956 | -0.0% | 0.01% | -10.0% |
| Q2 2023 | $21,526,639 | -1.3% | 1,913,479 | +1.1% | 0.01% | -9.1% |
| Q1 2023 | $21,799,976 | +5.8% | 1,892,359 | +6.4% | 0.01% | 0.0% |
| Q4 2022 | $20,610,508 | -9.0% | 1,778,301 | -0.3% | 0.01% | -8.3% |
| Q3 2022 | $22,643,000 | +88.7% | 1,782,871 | +2.1% | 0.01% | +100.0% |
| Q2 2022 | $11,999,000 | +5.7% | 1,746,481 | +48.3% | 0.01% | +20.0% |
| Q1 2022 | $11,355,000 | -19.9% | 1,177,948 | -1.2% | 0.01% | 0.0% |
| Q4 2021 | $14,178,000 | -22.2% | 1,192,398 | +6.3% | 0.01% | -28.6% |
| Q3 2021 | $18,215,000 | -16.4% | 1,121,613 | +8.3% | 0.01% | -12.5% |
| Q2 2021 | $21,796,000 | +50.7% | 1,035,947 | +11.2% | 0.01% | +33.3% |
| Q1 2021 | $14,462,000 | -54.2% | 931,205 | -38.0% | 0.01% | -53.8% |
| Q4 2020 | $31,546,000 | -10.6% | 1,502,205 | -14.0% | 0.01% | -23.5% |
| Q3 2020 | $35,283,000 | – | 1,747,557 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $19,891,505 | 30.79% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $44,363,675 | 23.76% |
| Atlas Venture Life Science Advisors, LLC | 9,885,449 | $88,573,623 | 13.72% |
| Logos Global Management LP | 2,180,000 | $19,532,800 | 2.61% |
| TCG Crossover Management, LLC | 1,650,150 | $14,785,344 | 2.18% |
| VR Adviser, LLC | 2,173,913 | $19,478,260 | 2.05% |
| Altium Capital Management LP | 315,000 | $2,822,400 | 1.47% |
| Vivo Capital, LLC | 1,035,136 | $9,274,819 | 1.02% |
| Octagon Capital Advisors LP | 692,945 | $6,208,787 | 0.95% |
| ACUTA CAPITAL PARTNERS, LLC | 146,500 | $1,312,640 | 0.88% |